The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off

被引:54
作者
Beig, Avital [1 ]
Miller, Jonathan M. [2 ]
Dahan, Arik [1 ]
机构
[1] Ben Gurion Univ Negev, Fac Hlth Sci, Sch Pharm, Dept Clin Pharmacol, IL-84105 Beer Sheva, Israel
[2] AbbVie Inc, Global Pharmaceut Res & Dev, N Chicago, IL USA
关键词
Low-solubility drugs; Intestinal permeability; Oral absorption; Cyclodextrins; Solubility-enabling formulations; Solubility-permeability interplay; ORAL FORMULATION DEVELOPMENT; WATER-SOLUBLE DRUGS; PHARMACEUTICAL APPLICATIONS; ENABLING FORMULATIONS; INCLUSION COMPLEXES; AQUEOUS-SOLUTION; LIPOLYSIS MODEL; INTERPLAY; ABSORPTION; DELIVERY;
D O I
10.1016/j.ejpb.2013.05.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to investigate the interaction of 2-hydroxypropyl-beta-cyclodextrin (HP beta CD) and 2,6-dimethyl-beta-cyclodextrin (DM beta CD) with the lipophilic drug nifedipine and to investigate the subsequent solubility-permeability interplay. Solubility curves of nifedipine with HP beta CD and DM beta CD in MES buffer were evaluated using phase solubility methods. Then, the apparent permeability of nifedipine was investigated as a function of increasing HP beta CD/DM beta CD concentration in the hexadecane-based PAMPA model. The interaction with nifedipine was CD dependent; significantly higher stability constant was obtained for DM beta CD in comparison with HP beta CD. Moreover, nifedipine displays different type of interaction with these CDs; a 1:1 stoichiometric inclusion complex was apparent with HP beta CD, while 1:2 stoichiometry was apparent for DM beta CD. In all cases, decreased apparent intestinal permeability of nifedipine as a function of increasing CD level and nifedipine apparent solubility was obtained. A quasi-equilibrium mass transport analysis was developed to explain this solubility-permeability interplay; the model enabled excellent quantitative prediction of nifedipine's permeability as a function of CD concentrations. This work demonstrates that when using CDs in solubility-enabling formulations, a trade-off exists between solubility increase and permeability decrease that must not be overlooked. This trade-off was found to be independent of the type of CD-drug interaction. The transport model presented here can aid in striking the appropriate solubility-permeability balance in order to achieve optimal overall absorption. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:1293 / 1299
页数:7
相关论文
共 47 条
[11]   The utility of cyclodextrins for enhancing oral bioavailability [J].
Carrier, Rebecca L. ;
Miller, Lee A. ;
Ahmed, Mran .
JOURNAL OF CONTROLLED RELEASE, 2007, 123 (02) :78-99
[12]   High-Throughput Phase-Distribution Method to Determine Drug-Cyclodextrin Binding Constants [J].
Chen, Zhi ;
Lu, Dujuan ;
Weber, Stephen G. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (01) :229-238
[13]   Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery [J].
Cirpanli, Yasemin ;
Bilensoy, Erem ;
Dogan, A. Lale ;
Calis, Sema .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 73 (01) :82-89
[14]   Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs [J].
Dahan, Arik ;
Hoffman, Amnon .
JOURNAL OF CONTROLLED RELEASE, 2008, 129 (01) :1-10
[15]   Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs:: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats [J].
Dahan, Arik ;
Hoffman, Amnon .
PHARMACEUTICAL RESEARCH, 2006, 23 (09) :2165-2174
[16]   The Solubility-Permeability Interplay and Its Implications in Formulation Design and Development for Poorly Soluble Drugs [J].
Dahan, Arik ;
Miller, Jonathan M. .
AAPS JOURNAL, 2012, 14 (02) :244-251
[17]   High-Permeability Criterion for BCS Classification: Segmental/pH Dependent Permeability Considerations [J].
Dahan, Arik ;
Miller, Jonathan M. ;
Hilfinger, John M. ;
Yamashita, Shinji ;
Yu, Lawrence X. ;
Lennernas, Hans ;
Amidon, Gordon L. .
MOLECULAR PHARMACEUTICS, 2010, 7 (05) :1827-1834
[18]   The Solubility-Permeability Interplay in Using Cyclodextrins as Pharmaceutical Solubilizers: Mechanistic Modeling and Application to Progesterone [J].
Dahan, Arik ;
Miller, Jonathan M. ;
Hoffman, Amnon ;
Amidon, Gregory E. ;
Amidon, Gordon L. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (06) :2739-2749
[19]   Cyclodextrin-based pharmaceutics: Past, present and future [J].
Davis, ME ;
Brewster, ME .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (12) :1023-1035
[20]   Violacein/β-cyclodextrin inclusion complex formation studied by measurements of diffusion coefficient and circular dichroism [J].
De Azevedo, MBM ;
Alderete, JB ;
Lino, ACS ;
Loh, W ;
Faljoni-Alario, A ;
Durán, N .
JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, 2000, 37 (1-4) :67-74